Page last updated: 2024-10-29

indolepropanol phosphate and Carcinoma

indolepropanol phosphate has been researched along with Carcinoma in 1 studies

indolepropanol phosphate: binds specifically to the alpha subunit, but not to the beta subunit of tryptophan synthase
3-(indol-3-yl)propyl phosphate : An monoalkyl phosphate compound having an O-3-(indol-3-yl)propyl substituent.

Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Varinelli, L1
Caccia, D1
Volpi, CC1
Caccia, C1
De Bortoli, M1
Taverna, E1
Gualeni, AV1
Leoni, V1
Gloghini, A1
Manenti, G1
Bongarzone, I1

Other Studies

1 other study available for indolepropanol phosphate and Carcinoma

ArticleYear
4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas.
    Endocrine-related cancer, 2015, Volume: 22, Issue:5

    Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell P

2015